Bristol-Myers Squibb Company (BMY) · page 144 of 197
Uses a 'contradiction' framework to contrast the Committee's charter requirements with the actual timeline of the Celgene acquisition.
Activist deck · expose_contradiction · expose_contradiction · overcrowded density
Slide locked Sign in to view
Slide schematic 7/9
callout 0/1 list 3/3 paragraph 1/1 quote 0/1 source-note 1/1 title 2/2
2 without position callout 1 · quote 1
calloutquote
Components 9
callout bullet bullet bullet paragraph quote source-note action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1